News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
246,806 Results
Type
Article (18062)
Company Profile (46)
Press Release (228698)
Section
Business (72487)
Career Advice (389)
Deals (12746)
Drug Delivery (27)
Drug Development (32087)
Employer Resources (44)
FDA (5704)
Job Trends (5390)
News (121849)
Policy (9324)
Tag
Academia (1872)
Alliances (20875)
Alzheimer's disease (626)
Approvals (5682)
Artificial intelligence (53)
Bankruptcy (53)
Best Places to Work (4716)
Breast cancer (50)
Cancer (545)
Cardiovascular disease (41)
Career advice (353)
CAR-T (35)
Cell therapy (115)
Clinical research (24542)
Collaboration (185)
COVID-19 (1412)
C-suite (35)
Cystic fibrosis (36)
Data (513)
Diabetes (34)
Diagnostics (2523)
Earnings (23591)
Employer resources (38)
Events (33880)
Executive appointments (127)
FDA (5907)
Funding (190)
Gene therapy (97)
GLP-1 (189)
Government (1590)
Healthcare (7821)
Infectious disease (1460)
Inflammatory bowel disease (44)
Interviews (53)
IPO (6269)
Job creations (851)
Job search strategy (315)
Layoffs (79)
Legal (1624)
Lung cancer (87)
Manufacturing (66)
Medical device (4387)
Medtech (4388)
Mergers & acquisitions (6613)
Metabolic disorders (114)
Neuroscience (725)
NextGen Class of 2024 (2475)
Non-profit (2199)
Northern California (624)
Obesity (64)
Opinion (90)
Patents (39)
People (23146)
Phase I (8466)
Phase II (11014)
Phase III (7649)
Pipeline (223)
Policy (39)
Postmarket research (795)
Preclinical (3856)
Radiopharmaceuticals (102)
Rare diseases (87)
Real estate (1884)
Regulatory (6572)
Research institute (1975)
Resumes & cover letters (39)
Southern California (493)
Startups (1586)
United States (5358)
Vaccines (269)
Weight loss (38)
Date
Today (49)
Last 7 days (370)
Last 30 days (1488)
Last 365 days (14252)
2024 (13001)
2023 (16216)
2022 (21055)
2021 (22721)
2020 (21686)
2019 (18036)
2018 (13584)
2017 (12822)
2016 (12141)
2015 (14432)
2014 (10471)
2013 (8650)
2012 (8891)
2011 (9423)
2010 (7932)
Location
Africa (271)
Arizona (58)
Asia (14911)
Australia (2916)
California (1318)
Canada (381)
China (88)
Colorado (54)
Connecticut (68)
Europe (33215)
Florida (213)
Georgia (41)
Illinois (133)
Indiana (62)
Japan (36)
Maryland (195)
Massachusetts (1014)
Minnesota (74)
New Jersey (423)
New York (426)
North Carolina (271)
Northern California (624)
Ohio (51)
Pennsylvania (318)
South America (453)
Southern California (493)
Texas (194)
Utah (33)
Washington State (224)
246,806 Results for "broad institute".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
GSK Wins Broad Label Expansion for Jemperli in First-Line Endometrial Cancer
In pursuit of Merck’s blockbuster Keytruda, GSK’s Jemperli scored its own broad FDA label expansion, allowing its use in first-line endometrial cancer regardless of biomarker status.
August 2, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Olympus Showcases a Broad Range of Solutions in Gynecology at AAGL
November 15, 2024
·
5 min read
Press Releases
Enveric Biosciences Announces Broad Range of Patent Issuances
November 5, 2024
·
5 min read
Business
Bayer and Broad Institute extend cancer therapy research collaboration
Bayer and the Broad Institute of MIT and Harvard have renewed their research alliance, adding five years to a 10-year collaboration that has already yielded three clinical oncology candidates.
November 2, 2023
·
3 min read
Drug Development
Osivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033
Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, announced that it has completed enrollment in its Phase 1 trial with OVX033, the company’s broad-spectrum vaccine candidate against sarbecoviruses.
June 25, 2024
·
3 min read
Pharm Country
A Novel Broad-Spectrum Antiviral with Activity Against Influenza A
NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes Influenza A viruses, possibly including Bird Flu H5N1 virus as well.
May 6, 2024
·
8 min read
Pharm Country
A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox
NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes activity against orthopoxvirus family, with both inhalation and skin abrasion modes of infection acquisition.
May 8, 2024
·
8 min read
Genetown
Exsilio Therapeutics Launches with $82 Million Series A Financing to Develop Redosable Genomic Medicines for A Broad Range of Diseases
Exsilio Therapeutics, a biotechnology company developing genomic medicines for a broad range of diseases, announced its emergence from stealth with $82 million in Series A financing.
June 25, 2024
·
3 min read
Business
Bayer and Broad Institute of MIT and Harvard Extend Research Collaboration to Develop New Cancer Therapies
Bayer and the Broad Institute of MIT and Harvard today announced that they have extended their research collaboration of 10 years by an additional five years, to develop and advance innovative cancer treatments.
November 2, 2023
·
4 min read
Pharm Country
A Novel Broad-Spectrum Antiviral with Activity Against RSV
NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, says that antiviral activity of NV-387 against RSV/A2 is strong enough to have resulted in full survival of lethally infected animals was achieved.
May 14, 2024
·
7 min read
1 of 24,681
Next
